Severe sepsis: Are PROWESS and PROWESS-SHOCK trials comparable? A clinical and statistical heterogeneity analysis

Critical Care

Volumn 17, Issue 4, 2013, Pages

  Kalil, Andre C ^a   Florescu, Diana F ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; DISEASE SEVERITY; HUMAN; MORTALITY; NONHUMAN; NOTE; PRIORITY JOURNAL; SEPSIS; STATISTICAL ANALYSIS; CLINICAL TRIAL (TOPIC); METHODOLOGY; TREATMENT OUTCOME;

ANTIINFECTIVE AGENT; DROTRECOGIN; PROTEIN C; RECOMBINANT PROTEIN;

ANTI-INFECTIVE AGENTS; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; HUMANS; PROTEIN C; RECOMBINANT PROTEINS; RESEARCH DESIGN; SEPSIS; TREATMENT OUTCOME;

EID: 84879798694     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc12752     Document Type: Note

References (7)

1. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709. 10.1056/NEJM200103083441001, 11236773.
2. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gardlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD, PROWESS-SHOCK Study Group Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012, 366:2055-2064. 10.1056/NEJMoa1202290, 22616830, PROWESS-SHOCK Study Group.
3. Levy MM, Artigas A, Phillips GS, Rhodes A, Beale R, Osborn T, Vincent JL, Townsend S, Lemeshow S, Dellinger RP. Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study. Lancet Infect Dis 2012, 12:919-924. 10.1016/S1473-3099(12)70239-6, 23103175.
4. Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, Wittebole X, Dugernier T, Perrotin D, Tidswell M, Jauregui L, Krell K, Pachl J, Takahashi T, Peckelsen C, Cordasco E, Chang CS, Oeyen S, Aikawa N, Maruyama T, Schein R, Kalil AC, Van Nuffelen M, Lynn M, Rossignol DP, Gogate J, Roberts MB, Wheeler JL, Vincent JL, ACCESS Study Group Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 2013, 309:1154-1162. 10.1001/jama.2013.2194, 23512062, ACCESS Study Group.
5. Kalil AC, Sun J. How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? A Bayesian design. Intensive Care Med 2008, 34:1804-1811. 10.1007/s00134-008-1159-8, 18504550.
6. Kalil AC, LaRosa SP. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression. Lancet Infect Dis 2012, 12:678-686. 10.1016/S1473-3099(12)70157-3, 22809883.
7. Kalil AC, Sun J. Why are clinicians not embracing the results from pivotal clinical trials in severe sepsis? A bayesian analysis. PLoS ONE 2008, 3:e2291. 10.1371/journal.pone.0002291, 2384005, 18509455.